Document resource
We read with great interest the randomised controlled trial by Singh et al regarding the efficacy of adjunctive dexamethasone in children with severe community-acquired pneumonia (CAP).1 We commend the authors for their innovative and significant contributions to the field, demonstrating a significant reduction in treatment failure at 72 hours, an outcome that may have substantial implications for paediatric clinical practice in resource-limited settings. However, we wish to offer a few points that may further enrich this discussion.